Patents by Inventor Tomas Cihlar

Tomas Cihlar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Remdesivir treatment methods
    Patent number: 11975012
    Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: May 7, 2024
    Assignee: Gilead Sciences, Inc.
    Inventor: Tomas Cihlar
  • DOSING AND SCHEDULING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES
    Publication number: 20240083984
    Abstract: Provided are methods for administering long-acting anti-HIV broadly neutralizing antibodies twice annually, e.g., Q6M, Q24W, Q25W or Q26W.
    Type: Application
    Filed: August 11, 2023
    Publication date: March 14, 2024
    Inventors: Yanan Zheng, Tomas Cihlar, Diana M. Brainard
  • Remdesivir treatment methods
    Patent number: 11903953
    Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: February 20, 2024
    Assignee: Gilead Sciences, Inc.
    Inventor: Tomas Cihlar
  • CAPSID INHIBITORS FOR THE PREVENTION OF HIV
    Publication number: 20240051941
    Abstract: The present disclosure provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of a compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided.
    Type: Application
    Filed: May 10, 2023
    Publication date: February 15, 2024
    Inventors: Elena Bekerman, Wade S. Blair, Anna Chiu, Tomas Cihlar, Dana J. Levine, Winston C. Tse, Stephen R. Yant, Jim X. Zheng
  • Capsid inhibitors for the prevention of HIV
    Patent number: 11807625
    Abstract: The present disclosure provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of a compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: November 7, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Elena Bekerman, Wade S. Blair, Anna Chiu, Tomas Cihlar, Dana J. Levine, Winston C. Tse, Stephen R. Yant, Jim X. Zheng
  • METHODS FOR TREATING SARS COV-2 INFECTIONS
    Publication number: 20230346812
    Abstract: Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted.
    Type: Application
    Filed: April 5, 2023
    Publication date: November 2, 2023
    Inventors: Tomas Cihlar, Anuoluwapo Osinusi, Danielle L. Porter
  • REMDESIVIR TREATMENT METHODS
    Publication number: 20230233587
    Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
    Type: Application
    Filed: March 30, 2023
    Publication date: July 27, 2023
    Inventor: Tomas Cihlar
  • Capsid inhibitors for the prevention of HIV
    Patent number: 11685728
    Abstract: The present disclosure provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of a compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: June 27, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Elena Bekerman, Wade S. Blair, Anna Chiu, Tomas Cihlar, Dana J. Levine, Winston C. Tse, Stephen R. Yant, Jim X. Zheng
  • Methods for treating SARS CoV-2 infections
    Patent number: 11660307
    Abstract: Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: May 30, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Tomas Cihlar, Anuoluwapo Osinusi, Danielle L. Porter
  • Multispecific antibodies that target HIV GP120 and CD3
    Patent number: 11597759
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: March 7, 2023
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Tomas Cihlar, Joshua Goldsmith, George Kukolj, Craig S. Pace, Doug Rehder, Matthew R. Schenauer, Derek Dean Sloan, Heather Theresa Stephenson, Nathan D. Thomsen
  • Remdesivir treatment methods
    Patent number: 11491169
    Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
    Type: Grant
    Filed: February 22, 2022
    Date of Patent: November 8, 2022
    Assignee: Gilead Sciences, Inc.
    Inventor: Tomas Cihlar
  • REMDESIVIR TREATMENT METHODS
    Publication number: 20220175805
    Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
    Type: Application
    Filed: February 22, 2022
    Publication date: June 9, 2022
    Inventor: Tomas Cihlar
  • REMDESIVIR TREATMENT METHODS
    Publication number: 20210393653
    Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
    Type: Application
    Filed: May 28, 2021
    Publication date: December 23, 2021
    Inventor: Tomas Cihlar
  • METHODS FOR TREATING SARS COV-2 INFECTIONS
    Publication number: 20210283150
    Abstract: Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted.
    Type: Application
    Filed: January 26, 2021
    Publication date: September 16, 2021
    Inventors: Tomas Cihlar, Anuoluwapo Osinusi, Danielle L. Porter
  • CAPSID INHIBITORS FOR THE PREVENTION OF HIV
    Publication number: 20210188815
    Abstract: The present disclosure provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of a compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided.
    Type: Application
    Filed: November 25, 2020
    Publication date: June 24, 2021
    Applicant: Gilead Sciences, Inc.
    Inventors: Elena Bekerman, Wade S. Blair, Anna Chiu, Tomas Cihlar, Dana J. Levine, Winston C. Tse, Stephen R. Yant, Jim X. Zheng
  • MULTISPECIFIC ANTIBODIES THAT TARGET HIV GP120 AND CD3
    Publication number: 20200377592
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Application
    Filed: May 6, 2020
    Publication date: December 3, 2020
    Inventors: Tomas Cihlar, Joshua Goldsmith, George Kukolj, Craig S. Pace, Doug Rehder, Derek Dean Sloan, Heather Theresa Stephenson, Nathan D. Thomsen
  • TOPICAL ANTIVIRAL FORMULATIONS
    Publication number: 20200069708
    Abstract: The present invention relates to formulations of antiviral compounds, in particular [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), suitable for topical application, and to their use in the reduction of or prevention of acquisition and transmission of herpes simplex virus.
    Type: Application
    Filed: January 18, 2019
    Publication date: March 5, 2020
    Inventors: Tomas Cihlar, Quarraisha Abdool Karim, Salim S. Abdool Karim, Ayesha Kharsany, James Francis Rooney
  • MULTISPECIFIC ANTIBODIES THAT TARGET HIV GP120 AND CD3
    Publication number: 20180371086
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Application
    Filed: June 21, 2018
    Publication date: December 27, 2018
    Applicant: Gilead Sciences, Inc.
    Inventors: Tomas Cihlar, Joshua Goldsmith, Craig S. Pace, Derek Sloan, Heather Stephenson, Nathan D. Thomsen, George Kukolj, Doug Rehder
  • Compounds and combinations for the treatment of HIV
    Patent number: 10059697
    Abstract: Provided are compounds, compositions, combinations, kits, uses, and methods for treating HIV in a human being using such compounds or combinations with proteasome inhibitors.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: August 28, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Tomas Cihlar, Michael Graupe, Yunfeng Eric Hu, Jeffrey Patrick Murry, Derek Dean Sloan, George Stepan, Helen Yu
  • TOPICAL ANTIVIRAL FORMULATIONS
    Publication number: 20180042946
    Abstract: The present invention relates to formulations of antiviral compounds, in particular [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), suitable for topical application, and to their use in the reduction of or prevention of acquisition and transmission of herpes simplex virus.
    Type: Application
    Filed: February 24, 2017
    Publication date: February 15, 2018
    Inventors: Tomas Cihlar, Quarraisha Abdool Karim, Salim S. Abdool Karim, Ayesha Kharsany, James Francis Rooney